Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 18, 2009

View Archived Issues

DMC recommends continuation of two phase III trials of salmon calcitonin in osteoporosis

QLT initiates phase Ib study of QLT-091001 in Leber's congenital amaurosis

Recombinant protein TAT/54R/KDEL inhibits CXCR4/CXCR12 interaction

Novel agent may shed light on formin activity in metastasis

Vitae Pharmaceuticals describes novel antidiabetic compounds

Institute for OneWorld Health claims CFTR inhibitors for the treatment of diarrhea

Solvay presents novel CB1 receptor antagonists for obesity therapy

Orexin receptor antagonists in development at GSK for the treatment of sleep disorders

Incyte identifies JAK inhibitors for cancer therapy

Can-Fite BioPharma to initiate phase II trial of CF-101 in glaucoma

Femta and Lonza sign manufacturing services agreement for FM-101 for RA

Ludwig Institute to study Pro-Pharmaceuticals' chemoprotective anticancer agent Davanat

Enrollment initiated in clinical trial of influenza vaccine in HIV-positive adults

Chelsea Therapeutics to change enrollment and primary endpoint of phase III droxidopa trial

Enrollment completed in first stage of phase II/III trial of C-Cure stem therapy for heart failure

Addex and Merck & Co. extend Parkinson's disease research collaboration

FOV-2304 prevents retinal edema and inflammation in rat model of diabetic retinopathy

PRO-131921 shows clinical activity in rituximab-relapsed/refractory indolent NHL patients

Phase II data of cediranib plus fulvestrant in metastatic breast cancer disclosed

Jazz Pharmaceuticals submits NDA to FDA for JZP-6 for the treatment of fibromyalgia

Antisoma announces results of phase II trial of AS-1411 in kidney cancer

Cubist Pharmaceuticals completes acquisition of Calixa Therapeutics

Achillion reports proof-of-concept data on ACH-1625 in hepatitis C

Auxilium reports topline phase IIb results of Xiaflex in Peyronie's disease

Taspoglutide meets primary endpoints in head-to-head phase III studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...